Status:
COMPLETED
Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice
Lead Sponsor:
Roswell Park Cancer Institute
Collaborating Sponsors:
Pfizer
Conditions:
Anatomic Stage IV Breast Cancer AJCC v8
Breast Carcinoma
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
This trial studies the impact of the breast cancer pathways program on the patient experience, including decision making and quality of life. Measuring how the breast cancer pathways program affects d...
Detailed Description
PRIMARY OBJECTIVES: I. Evaluate the impact of breast cancer pathways on patient experience, burden of decision making and quality of life in tertiary cancer center and community oncology practice. I...
Eligibility Criteria
Inclusion
- Treatment includes intravenous chemotherapy for breast cancer for primary disease as neoadjuvant or adjuvant therapy, or for recurrent and/or metastatic cancer
- Can provide consent
- Are able to comprehend written materials in English or Spanish
- Will receive their chemotherapy at Roswell Park sites in Buffalo or Amherst, New York (NY), or Roswell Park Oncology primary care (PC) sites in Niagara Falls, Amherst, West Seneca, or Jamestown NY
Exclusion
- Breast cancer patients receiving oral therapy alone
- Patients who are not able to comprehend written materials in English or Spanish
- Patients who will not receive chemotherapy at a Roswell Park site
- Patients who are not able to comprehend written materials will not be included in this study, as the consent document will be administered in multiple infusion centers that cannot be all staffed daily with a research associate. The study instruments used are standardized tools that have been developed as best as possible with appropriate literacy levels
- Patients enrolled in clinical trials for their breast chemotherapy will be excluded from this study because they will require alternative educational materials that are specific to the trial drugs being administered
Key Trial Info
Start Date :
February 6 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2022
Estimated Enrollment :
174 Patients enrolled
Trial Details
Trial ID
NCT04297384
Start Date
February 6 2019
End Date
August 30 2022
Last Update
April 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263